Table 1.

Summary of the total cutaneous adverse reactions reported to the Pharmacovigilance Service of Trieste (patients nr.1–44), including those evaluated at the Dermatology Clinic of Trieste (patients nr.38–44) and in other clinics of the Friuli Venezia‐Giulia region, in Northeast Italy (patients 45–46)

Patient	Sex, Age	Cutaneous adverse reaction, timing of onset (if specified)	First or Second dose
1	F, 55	Urticarial rash limited to the upper limbs	First
2	F, 27	Urticarial rash limited to the neck and chest	Not reported
3	F, 64	Itchy erythema of the neck and hands	First
4	M, 38	Itching at the inoculation site	First
5	F, 49	Erythema at the inoculation site	First
6	F, 23	Urticarial rash limited to the chest	First
7	F, 49	Itchy erythema of the palms	First
8	F, 32	Itchy dermatitis of the face with fever	First
9	F, 34	Generalized itching	First
10	F, 37	Morbilliform eruption	Not reported
11	F, 43	Painful and itchy erythematous subcutaneous nodule at the inoculation site, 3 days after the dose	First
12	F, 50	Erythema of the chest and hands	First
13	F, 34	Urticarial rash limited to the upper limbs	First
14	F, 53	Painful hardening of the skin at the inoculation site with fever	Second
15	F, 65	Swelling of the face, 18 h after the dose	First
16	F, 51	Itchy arm with axillary lymphadenopathy, 24 h after the dose	First
17	F, 57	Painful swelling and erythema of the right eyelid, 7 days after the dose	First
18	F, 52	Generalized itching	First
19	F, 46	Burning wheal at the inoculation site	First
20	F, 63	Itchy wheal at the inoculation site	First
21	M, 28	Itchy swelling at the inoculation site	First
22	F, 56	Erythematous and itchy hardening of the skin at the inoculation site with fever	Second
23	F, 34	Herpes Zoster of the scalp	First
24	F, 46	Erythema at the inoculation site, 1 day after the dose	First
25	F, 46	Urticarial rash limited to the chest and lower limbs	First
26	F, 37	Cutaneous rash of the trunk	Second
27	F, 46	Generalized itching	First
28	F, 65	Nodule following itchy erythema at the inoculation site	First
29	F, 37	Painful wheal at the inoculation site	First
30	F, 55	Erythema at the inoculation site with fever	Second
31	F, 37	Swelling of the eyelids and face with mandibular lymphadenopathy	First
32	M, 70	Erythema at the inoculation site	First
33	F, 26	Painful swelling at the inoculation site	First
34	F, 39	Wheal at the inoculation site with axillary lymphadenopathy	First
35	F, 36	Itchy erythema of the abdomen, 1 week after the dose	First
36	F, 35	Swelling at the inoculation site with fever	Second
37	F, 48	Herpes Zoster	First
38 Fig. 1a–b	F, 54	Diffuse urticaria, 5 days after the dose	First
39 Fig. 1e	F, 41	Erythematous macular rash of the hands, 8 days after the dose	First
40 Fig. 1f	F, 44	Purplish macule on the third finger of one hand (fixed drug eruption), 10 days after the dose	Second
41 Fig. 1g	F, 42	Pityriasis rosea‐like rash on the thighs and abdomen, 4 days after the dose	Second
42	M, 64	Pityriasis rosea‐like rash on the neck, upper limbs, and trunk, 5 days after the dose	First
43	M, 18	Diffuse urticaria, 60 h after the dose	First
44	F, 55	Malar erythema, 12 h after the first dose; erythema of the face, trunk and thighs with fever, 3 days after the second dose	First and second
45 Fig. 1c	F, 34	Diffuse urticaria; transient periorbital and perioral swelling, 4 days after the dose	First
46 Fig. 1d	F, 27	Chilblain‐like rash on the first and third finger of one foot accompanied by urticarial rash, 4 days after the first dose; urticarial rash, 1 day after the second dose	First and second

Data were collected during the vaccination campaign with Comirnaty®‐BioNTech/Pfizer (m‐RNA COVID‐19 vaccine) in January 2021.